For instance, inhibitors targeting the RNA-binding protein HuR, such as the small molecule MS-444, prevent HuR from binding to its RNA targets, which has shown promise in reducing tumor growth in certain cancers93 and small molecule modulators of splicing, such as Risidiplam that has been approved for the treatment of spinal muscular atrophy94. This evidence concerns the gene ELAVL1 and neoplasm.